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Abstract
Developmental biology, regenerative medicine and cancer biology are more and more interested in
understanding the molecular mechanisms controlling pluripotency and self-renewal in stem cells.
Pluripotency is maintained by a synergistic interplay between extrinsic stimuli and intrinsic circuitries,
which allow sustainment of the undifferentiated and self-renewing state. Nevertheless, even though a lot
of efforts have been made in the past years, the precise mechanisms regulating these processes remain
unclear. One of the key extrinsic factors is leukemia inhibitory factor (LIF) that is largely used for the
cultivation and derivation of mouse embryonic and induced pluripotent stem cells. LIF acts through the
LIFR/gp130 receptor and activates STAT3, an important regulator of mouse embryonic stem cell
self-renewal. STAT3 is known to inhibit differentiation into both mesoderm and endoderm lineages by
preventing the activation of lineage-specific differentiation programs. However, LIF activates also
parallel circuitries like the PI3K-pathway and the MEK/ERK-pathway, but its mechanisms of action
remain to be better elucidated. This review article aims at summarizing the actual knowledge on the
importance of LIF in the maintenance of pluripotency and self-renewal in embryonic and induced
pluripotent stem cells
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Abstract: Developmental biology, regenerative medicine and cancer biology are more and 
more interested in understanding the molecular mechanisms controlling pluripotency and 
self-renewal in stem cells. Pluripotency is maintained by a synergistic interplay between 
extrinsic stimuli and intrinsic circuitries, which allow sustainment of the undifferentiated 
and self-renewing state. Nevertheless, even though a lot of efforts have been made in the 
past years, the precise mechanisms regulating these processes remain unclear. One of the 
key extrinsic factors is leukemia inhibitory factor (LIF) that is largely used for the 
cultivation and derivation of mouse embryonic and induced pluripotent stem cells. LIF acts 
through the LIFR/gp130 receptor and activates STAT3, an important regulator of mouse 
embryonic stem cell self-renewal. STAT3 is known to inhibit differentiation into both 
mesoderm and endoderm lineages by preventing the activation of lineage-specific 
differentiation programs. However, LIF activates also parallel circuitries like the  
PI3K-pathway and the MEK/ERK-pathway, but its mechanisms of action remain to be 
better elucidated. This review article aims at summarizing the actual knowledge on the 
importance of LIF in the maintenance of pluripotency and self-renewal in embryonic and 
induced pluripotent stem cells. 
OPEN ACCESS 
Genes 2011, 2                            
 
 
281 
Keywords: LIF; STAT3; pluripotency; embryonic stem cells; induced pluripotent 
stem cells 
 
1. Introduction 
The Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway mediates the 
transmission of information received from extracellular polypeptide signals, through transmembrane 
receptors and directly targets gene promoters without needing second messengers. Leukemia inhibitory 
factor (LIF) belongs to the family of interleukin (IL)-6-type cytokines, which signal through the 
common receptor subunit gp130 in association with a ligand-specific receptor subunit, the low-affinity 
LIF receptor (LIFR). The binding of LIF to the LIFR induces its heterodimerization with gp130. The 
formation of this complex results in the activation of the receptor-associated Janus kinases (JAKs), in 
the phosphorylation of receptor docking sites, and finally in the recruitment of Src homology-2 (SH2) 
domain containing proteins such as STAT3 (signal transducer and activator of transcription 3). When 
bound to the receptor, STAT3 molecules are phosphorylated on tyrosine 705 (Tyr705) residues and 
dimerize with another phosphorylated STAT3. The dimers are then translocated to the nucleus in a 
regulated manner where they bind to promoters and enhancer regions of their target genes (Figure 1). 
The suppressor of cytokine signaling 3 (SOCS3) is an important negative regulator of the  
LIF/STAT3-pathway whose expression is directly driven by STAT3. SOCS3 plays a critical role in 
many cell types and tissues in which the LIF-pathway is active.  
Figure 1. Schematic representation of the LIF-pathway. 
 
In parallel to the activation of the STAT3-pathway, the binding of LIF to the LIFRβ/gp130 receptor 
leads to the activation of the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol-3 
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phosphate kinase (PI3K) pathways. Together with the JAK/STAT3-pathway they are essential 
components for the regulation of biological responses in embryonic stem cells (ESCs). Active gp130 
receptor can associate with the protein tyrosine phosphatase SHP-2 [1], a positive effector of the 
MAPK signaling cascade, and lead to recruitment of Gab1. The complex gp130/SHP-2/Gab1 initiates 
a phosphorylation cascade that culminates in the activation of the ERK1 and ERK2 kinases [2] (Figure 1). 
Last but not least, LIF binding to the LIFRβ/gp130 receptor induces the activation of members of the 
class IA family of phosphatidylinositol-3 phosphate kinases (PI3Ks). PI3Ks mediate signal transduction 
through downstream effector molecules including the serine/threonine protein kinase B (PKB, also 
known as AKT) that has been implicated in many cellular processes like regulation of the cell cycle 
progression, cell death, adhesion, migration, metabolism and tumorigenesis (for review see [3]). GSK3β 
(glycogen synthase kinase 3β) is a common target of the PI3K/AKT-pathway and of the Wnt-pathway. 
These pathways control GSK3β phosphorylation thereby regulating its inactivation (Figure 1). 
2. The LIF Signaling Pathway and Pluripotency 
2.1. The Role of LIF/STAT-Pathway during Preimplantation Development  
Preimplantation embryos express LIF, LIFβR and gp130 mRNA highlighting a possible function of 
the LIF/STAT3-pathway in vivo. However, studies on knockout mouse models indicate that at least the 
early embryonic development can occur also in the absence of some components of the  
LIF-pathway but many of these mouse models then display later on during development or during 
adulthood many different disorders (Table 1). Lif−/− embryos, for instance, develop normally into 
adulthood [4,5] but even though Lif−/− females are fertile, their blastocysts cannot implant due to the 
absence of LIF production by the uterus. This is of note because p53−/− mice display the same 
implantation defects as Lif−/−. Interestingly, development of both p53−/− and Lif−/− embryos can be 
rescued by transferring them to a wild-type female [6]. Another example are embryos carrying 
mutations on the LIFβR, which also develop to term but have alterations in the fetal liver metabolism, 
in the formation of bones, and in the survival of astrocytes and motor neurons in the spinal cord and 
brain stem [7,8]. Last but not least, gp130−/− embryos are able to develop to blastocysts and to implant 
but die between day 12 to 16 of embryogenesis with cardiac, hematopoietic and neuronal disorders [9].  
These findings demonstrate that the LIF-pathway is dispensable in vivo during preimplantation. 
However, ESCs are believed to be the in vitro counterpart of the transient pool of pluripotent cells 
present in the early epiblast, but are in contrast to the cells of the embryos, LIF-dependent.  
In mice, a possible explanation for this discrepancy is the existence of a phenomenon called 
diapause. Mice can temporarily arrest embryogenesis at the blastocyst stage thereby overcoming 
suboptimal conditions for reproduction. During diapause the embryos develop to the hatched 
blastocyst stage but stop their development, remaining unimplanted in the uterus. During this period 
that can persist for weeks, the epiblast cells have to be maintained as pluripotent until the development 
of the embryo is restored. Interestingly, diapause-arrested embryos carrying mutations on the LIFβR 
and the gp130 receptors fail to restore normal embryogenesis [10]. This highlights the absolute 
requirement for LIF/gp130 signaling in the epiblast during diapause. ESCs were first established from 
diapause embryos [11] and this could represent a potential explanation why ESCs are LIF dependent. 
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Table 1. Effect of gene targeting and overexpression of leukemia inhibitory factor (LIF)—
pathway members in vivo and in ESCs. 
Gene/Protein KO/overexpression in vivo KO/overexpression in ESCs Literature 
LIF Viable, Lif−/− females are fertile, 
but their blastocysts cannot implant. 
LIF overexpression is lethal and 
leads to the absence of differentiated 
mesoderm. Embryos do not undergo 
normal gastrulation. 
Lif−/− ESCs cannot be derived 
under classical culture conditions. 
[12] 
[13] 
[14] 
[4] 
gp130 
gp130−/− embryos can survive 
diapause but the epiblast 
compartment is not maintained. 
They die between E12.5 and E16 
because of developmental defects.  
gp130−/− ESCs cannot be derived 
under classical culture conditions. 
Modest gp130 overexpression 
enhances self-renewal in the 
absence of exogenous LIF, greater 
levels of receptor expression 
increases differentiation. 
[9] 
[10] 
[15] 
[13] 
LIFR Lifr−/− embryos die around the time 
of birth with severe deficits in motor 
neuron and glial cell populations. 
Lifr−/− embryos do not survive 
prolonged diapause. 
Lifr−/− ESCs cannot be derived 
under classical culture conditions. 
[16] 
[8] 
[10] 
[13] 
STAT3 
Stat3 null embryos undergo normal 
initial formation and growth of the 
epiblast but gastrulation is disrupted. 
Stat3 null ESCs can only be 
derived under 2i conditions. 
STAT3 overexpression is 
sufficient to maintain ESCs 
pluripotent in absence of LIF. 
[17] 
[18] 
[19] 
SOCS3 
Essential for maintenance of murine 
ESC pluripotency and trophoblast 
differentiation. 
Socs3 null cells show enhanced 
activation of STAT3 and SHP2. 
[20] 
[21] 
[22] 
[23] 
[24] 
[25] 
JAK1 JAK1 is essential for the 
differentiation of the trophoblast. 
Jak−/− mice die within the first 24 
hours after birth. 
JAK1 is essential for LIF signaling 
in ESCs. 
[25] 
[26] 
[27] 
[28] 
JAK2 
Jak2−/− embryos are anemic and die 
around day 12.5 postcoitum  
Jak2−/− ESCs are competent for 
LIF signaling. JAK2 plays a role in 
early lineage decision. 
[29] 
[26] 
Shp2 Shp2 null blastocysts initially 
develop normally, but they 
subsequently exhibit inner cell mass 
death, reduced number of 
trophoblast giant cells, and failure to 
yield trophoblast stem cell lines. 
Homozygous null mutants die at 
embryonic day 10.5 
Deletion of Shp2 in mouse ESCs 
inhibits differentiation. Shp2 null 
ESCs show increased STAT3 
phosphorylation after LIF 
stimulation. 
[30] 
[31] 
[32] 
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2.2. Establishing and Maintaining Pluripotent Stem Cells in vitro  
Pluripotent stem cells harbor two important properties: the capacity of indefinite self-renewal  
in vitro and the ability to contribute to the formation of all cells of an adult organism including the 
generation of functional gametes for genome transmission. Due to their pluripotent state these cells can 
be used for various applications, like the generation of knockout or transgenic animals, and potentially 
as a cell source for cell therapy in regenerative medicine.  
Two types of murine pluripotent stem cells can be derived. The embryonic stem cells (ESCs) which 
are isolated from the inner cell mass (ICM) of blastocyst stage embryos [11,33] and the induced 
pluripotent stem cells (iPSCs), which are generated by reprogramming somatic cells using gene 
transfection [34]. Murine pluripotent ESCs are characterized by the expression of specific cell surface 
glycoproteins such as the stage-specific embryonic antigen 1 (SSEA-1) [35] as well as by the presence 
of transcription factors like OCT3/4 [36,37] and Nanog [38,39]. Furthermore, ESCs express elevated 
levels of alkaline phosphatase and have high telomerase activity [40].  
It is a combinatorial activity of different signaling pathways that orchestrates the maintenance of 
ESCs in a pluripotent state. For example, it has been shown that bone morphogenetic protein (BMP) 
enhances self-renewal and pluripotency of ESCs in the presence of LIF [41]. Moreover, activation of 
the canonical WNT-pathway was shown to maintain the undifferentiated phenotype in both mouse and 
human ESCs, and to sustain expression of the pluripotency markers like OCT4, REX1 (zinc-finger 
protein-42; ZFP42) and Nanog in the absence of LIF [42]. Furthermore, nutrients and other 
environmental cues, like amino acids [43] and inositols [44], are also involved in the regulation of 
early mouse embryos and ESCs survival.  
2.2.1. The Role of LIF in Pluripotent Stem Cells 
Murine ESCs are routinely isolated and maintained in vitro by using mitotically inactivated 
embryonic fibroblasts (feeders) and fetal calf serum. In 1988, LIF was identified as a paracrine signal 
produced from the feeders preventing stem cell differentiation while promoting ESC self-renewal  
[45–47]. In the following years, ESC culture conditions have been constantly improved, so that for 
example, feeders could be substituted through addition of LIF to the medium whereas serum could be 
replaced through addition of BMP [48].  
Only recently, new defined culture conditions free from feeders, serum and cytokines, were 
established by using a combination of small-chemical molecules, which inhibit the mitogen-activated 
protein kinase (MAPK)/extracellular signal-related kinase (ERK1/2) and the glycogen synthase kinase 3 
(GSK3). Under these conditions (2i), it was possible to maintain self-renewal in the absence of 
LIF/STAT3 stimulation as shown by the fact that in ESCs cultivated under these conditions neither 
STAT3 nor SOCS3 activation was detected. Moreover, the presence of 2i allowed the establishment of 
Stat3 null cells [19]. Nevertheless, addition of LIF to the 2i culture conditions maximizes clonogenic 
self-renewal of ESCs, highlighting once more the importance of LIF in ESC maintenance.  
As mentioned before, in mouse ESCs LIF does not only activate the STAT3-mediated cascade, but 
also induces the PI3K-pathway and the ERK-pathway. The PI3K-pathway is involved in the 
maintenance of pluripotency [49–51], whereas the ERK-pathway along with the FGF-pathway induces 
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pro-differentiative programs [52,53]. These observations strongly suggest that several LIF induced 
pathways are concomitantly necessary for the maintenance of ESC identity. 
The importance of the LIF-pathway components in derivation and maintenance of ESCs has 
extensively been studied. The LIFR receptor is not sufficient to mediate the signal to maintain ESC 
self-renewal, whereas gp130 is [54], indicating that gp130 is the main component of the activated 
LIFR/gp130 receptor. Moreover, ESCs can be derived and maintained using a combination of 
interleukin-6 and soluble interleukin-6 receptor (IL-6/sIL-6R) [55,56], which induces the 
homodimerization of gp130 and the activation of signaling processes that sustain self-renewal of 
ESCs. These studies indicate that signals mediated from gp130 are sufficient for self-renewal. 
Moreover, STAT3 activation is essential for LIFR/gp130-mediated ESC self-renewal [54] and its 
constitutive expression is sufficient for keeping ESCs pluripotent in the absence of LIF [18]. 
Nevertheless, the downstream components activated by LIF are still not completely understood and 
especially how LIF is mediating the activation of the MAPK- and PI3K-pathways has not yet  
been clarified. 
2.2.2. The LIF/STAT-Pathway in Embryonic Stem Cells 
STAT3 activation has previously been shown to be necessary and sufficient to maintain  
self-renewal of mouse ESCs in the presence of serum or serum replacement [18,54,57,58]. Matsuda 
and colleagues used a chimeric STAT3-modified estrogen receptor (STAT3MER) composed of the 
entire coding region of STAT3 and the ligand-binding domain of the estrogen receptor. Dimerization 
of the chimeric STAT3 was activated after treatment with the estrogen derived 4-hydroxy-tamoxifen 
(OHT). ESCs cultivated in the presence of OHT were able to self-renew in the absence of LIF. The 
importance of STAT3 in ESCs is further supported by the observation that inactivation of Stat3 by a 
dominant interfering mutant (STAT3F) in LIF-maintained ESCs promotes spontaneous differentiation 
[54]. In a recent study, by using the same STAT3 inducible system, we were able to generate ESCs 
from the non-permissive FVB/N mouse strain in the presence of 4-OHT with high efficiency [58], 
highlighting the importance of this factor also in the derivation of ESCs from the ICM of  
the blastocysts.  
Even though these observations provide evidence for the role of STAT3 as an important component 
of the LIF-dependent self-renewal in ESCs, the downstream target genes of activated STAT3 have 
remained elusive. Several studies based on chromatin immunoprecipitation (ChIP) analysis or on 
microarray technology have recently been performed aiming at the identification of these genes  
[58–63]. The transcription factor c-MYC was described to play an important role in self-renewal by 
functioning as a key target of LIF/STAT3 signaling [62]. Constitutive expression of c-Myc renders 
self-renewal independent of LIF [62], a phenomenon that was described also for other genes involved 
in the maintenance of pluripotency, such as Nanog [39], Klf2 [64], Pem/Rhox5 [58,65] and Pramel7 
[58,66]. On the other hand expression of a dominant negative form of c-MYC promotes differentiation 
[62]. c-MYC is a transcription factor that controls many different biological processes, such as cell 
proliferation, growth, differentiation and apoptosis. Moreover, c-Myc is, together with OCT3/4, KLF4, 
and SOX2, one of the transcription factors able to reprogram somatic cells into undifferentiated  
iPSCs [34].  
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A link between STAT3 and other pluripotency related genes has also been described. A recent study 
showed that 55% of the putative STAT3 target genes display binding sites for Nanog, and 41% of the 
putative Nanog target genes display binding sites for STAT3 [67]. These results highlight the fact that 
these transcription factors co-regulate the expression of a large number of target genes involved in the 
maintenance of the undifferentiated state in ESCs. Another study identified 24 STAT3 target genes 
which showed binding sites for STAT3 and/or Nanog. Knockdown of these genes increased 
differentiation of ESCs in LIF-supportive conditions, confirming their contribution to pluripotency 
[63]. Some of the identified genes were already known to be STAT3 targets, like Pim-1 and  
Pim-3 kinases [68] and two genes of the Krüppel-factors family, namely Klf4 and Klf5. Klf4 was 
recently proposed as a downstream target of LIF/STAT3 also by other research groups [64,69]. 
LIF/STAT3 selectively induces Klf4 but its overexpression is not sufficient to sustain prolonged ESC 
self-renewal in the absence of LIF or STAT3 [64].  
We could recently identify Pramel7 as a new STAT3 target gene [66]. Ablation of Pramel7 in ESCs 
induces differentiation, while its overexpression is sufficient to support long-term self-renewal in the 
absence of exogenous LIF and suppresses differentiation. LIF-mediated Pramel7 expression involves 
both STAT3-dependent transcriptional regulation and PI3K-dependent phosphorylation of GSK3. 
Pramel7 expression in turn confers constitutive self-renewal and prevents differentiation through 
inactivation of ERK phosphorylation. Moreover, Pramel7 knockdown induced ESC differentiation in 
the presence of LIF and upon forced STAT3 activation, indicating that Pramel7 is a mediator of the 
LIF- and STAT3-dependent maintenance of pluripotency in ESCs. Therefore, Pramel7 represents a 
central and essential factor in the signaling network regulating pluripotency and self-renewal in  
ESCs [66]. 
A further component of the LIF/STAT3-pathway is SOCS3, a STAT3-dependent repressor that 
attenuates LIF signaling. Different studies showed that SOCS3 is essential for maintenance of murine 
ESC pluripotency and for trophoblast differentiation [21–25]. LIF binding to the LIFR/gp130 
heterodimer induces auto-phosphorylation of associated JAK1 (pJAK1), which subsequently 
phosphorylates the receptor tyrosines. Upon binding to phosphorylated tyrosines on gp130, STAT3 
becomes phosphorylated, dimerizes and translocates to the nucleus where it induces transcription of 
SOCS3. SOCS3 binds to phosphorylated tyrosine 757 on gp130 and may undergo a conformational 
change. SOCS3 then binds to pJAK1 and the complex is released from the receptor complex. This 
inhibits further STAT3 activation, as tyrosines within the intracellular domain are no longer being 
phosphorylated by JAK1. SOCS3 bound pJAK1 promotes the proteasomal degradation of pJAK1 [20]. 
2.2.3. The LIF/ERK/MEK-Pathway 
ERK has been shown to regulate early differentiation in vivo and in vitro [52,70]. Upon LIF 
stimulation, both ERK1 and ERK2 are activated through phosphorylation by SHP-2 [71]. 
Nevertheless, suppression of SHP-2/ERK does not affect the propagation of stem cells, but on the 
contrary enhances ESCs self-renewal [71]. This indicates that SHP-2/ERK signaling activation is 
necessary for the normal differentiation processes. ERK signaling is also involved in the regulation of 
proliferation and survival of somatic cells [72] and in the regulation of early preimplantation 
development. Phosphorylated ERK has been detected from the 2-cell stage embryo until the blastocyst 
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stage [73]. Incubation of 2-cell stage embryos with an ERK inhibitor results in a developmental arrest 
at the four-cell stage embryo, however the development can be restored once the inhibitor is removed 
[74]. This confirms that the ERK-pathway is required for progression of early cell division cycles in 
the preimplantation embryo. Entrance into the G1 phase of the cell cycle is a prerogative for cell 
differentiation. During the development from the 2-cell to the 8-cell stage embryo, ERK signaling 
seems to be essential in the G2/M transition [74]. This is in contrast to what is happening in many 
mammalian cells, where ERK activity is essential for the cell cycle progression from G0/G1 to S phase [75].  
Interestingly the ERK-pathway may be able to inhibit the JAK/STAT3-pathway at the level of 
STAT3. It has been shown that ESCs knocked out for Shp2 phosphatase after LIF stimulation showed 
an increased phosphorylation of STAT3 when compared to wild-type cells [31]. This data supports the 
evidence that the two pathways seem to converge and thereby determine the choice between  
self-renewal and differentiation (Figure 1). 
2.2.4. The LIF/PI3K-Pathway 
In ESCs the LIF/PI3K-pathway was initially implicated in the control of proliferation [76,77]. Later 
it could be demonstrated that LIF-induced PI3K signal activation is also involved in ESC  
self-renewal [51]. Incubation of ESCs with LIF and LY294002, a small chemical inhibitor of PI3K, 
showed a reduced ability of LIF to promote self-renewal and a reduction of alkaline phosphatase 
positive cells. Since under these conditions no changes in the phosphorylation levels of STAT3 could 
be detected, the observed loss of self-renewal and the consequent differentiation of the cells were 
explained by an increase in ERK phosphorylation upon LIF stimulation [51]. These findings are 
consistent with other studies where it was reported that PI3K plays a role in negatively regulating ERK 
activity in ESCs [78]. Paling et al. demonstrated that self-renewal was restored after incubation with 
both ERK and PI3K inhibitor, therefore confirming that the regulation of ERK activity by PI3K 
signaling contributes to the determination of ESCs self-renewal [51].  
The importance of PI3K/AKT signaling in the regulation of ESCs is also corroborated by the fact 
that expression of a myristoylated active form of AKT liberates ESCs from LIF-dependence. These 
cells showed no alteration in the level of phosphorylated STAT3 compared to the control cells, but 
interestingly exhibited increased ERK phosphorylation [50]. These findings are in contrast with the 
results from Paling et al. [51] indicating that increased ERK phosphorylation upon PI3K inhibition 
leads to differentiation. 
Wnt blocks proteasome-mediated degradation of β-catenin through the inhibition of GSK3β (for 
review see [79,80]). Additionally, β-catenin signaling has also been postulated to be involved in the 
AKT-mediated maintenance of the undifferentiated state. Although in transgenic ESCs expressing a 
constitutive active form of AKT, GSK3β phosphorylation was enhanced, β-catenin signaling was not 
activated. It was therefore concluded that AKT-dependent maintenance of the undifferentiated state in 
ESCs was independent from the Wnt/β-catenin signaling [50]. Long-term treatment of ESCs with the 
PI3K inhibitor LY294002 was shown to inhibit the proliferation and to induce cell cycle arrest at the 
G1 phase [77]. The PI3K/AKT is known to control cell-cycle regulation, where AKT promotes the 
G1/S-phase transition by facilitating the formation of cyclin/CDK complexes [3]. ESCs lack cell-cycle 
inhibitory mechanisms, which are typical of differentiated cells. They acquire these mechanisms only 
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upon withdrawal of LIF and consequent differentiation of the cells [81]. It is therefore possible that the 
AKT-mediated maintenance of self-renewal in ESCs is due to its ability to block the cell-cycle 
inhibitory mechanisms and consequently block differentiation [50]. Recently, it was shown that AKT1 
interacts with and phosphorylates SOX2 at a highly conserved threonine residue in self-renewing 
mouse ESCs. This modification leads to an enhanced transcriptional activity and to an increase in 
SOX2 protein which accumulates in the nucleus [82].  
2.3. LIF/STAT3 and Reprogramming 
Genome-wide epigenetic reprogramming occurs during normal mammalian development and 
consists in the erasure and remodeling of epigenetic marks, such as DNA methylation. This process is 
typically linked to the reversal of differentiation and can be exploited to re-establish the pluripotent 
state typical of ESCs. In the past years several reprogramming systems have been developed to restore 
pluripotency in somatic cells. The two most widely used methodologies are the somatic nuclear 
transfer (SCNT) and the generation of induced pluripotent stem cells (iPSCs). The first technology 
consists in the transfer of a somatic nucleus into an oocyte. Oocytes or zygotes are able to erase 
epigenetic information from the somatic nucleus [83–85]. Reconstituted embryos are able to proceed 
through the cleavage stages into the blastocyst stage. The success rate of SCNT is nevertheless 
extremely low. A more elegant way of reprogramming was recently introduced by Takahashi and 
Yamanaka [34,86,87]. This technology consists in the transfection of differentiated cells with the 
master transcriptional regulators Oct3/4 (Pou5f1) and Sox2, in combination with c-Myc and Klf4. This 
work was followed by a number of further publications from different laboratories that contributed to 
various improvements of the original protocol. Meanwhile several different combinations of 
transcription factors have been shown to be sufficient to induce reprogramming. For example, the 
combinations of Nr5a2, Sox2, Klf4, and c-Myc [88] or Oct3/4, Nanog, Klf4, and c-Myc or Oct4, Sox2, 
Nanog, and Lin28 [89] were described. Nevertheless, the in vitro reprogramming process is still very 
inefficient and requires considerably more time than the reprogramming processes that occur in vivo. 
Further analysis of the mechanisms underlying reprogramming in vivo and in vitro are needed in order 
to improve this technology. 
After transduction of the reprogramming factors and throughout the reprogramming process, the 
cells need to be maintained in the presence of LIF. Until recently it was unclear if LIF and its 
downstream target STAT3 maximize the self-renewal of the newly generated iPSCs or do have an 
active role in the reprogramming process. In a recent work, Yang and colleagues demonstrated that 
STAT3 cooperates with the reprogramming factors and directly contributes to the induction and 
reactivation of the endogenous pluripotency network to generate iPSCs [90]. The authors of this study 
used an engineered chimeric GCSFR/gp130 receptor that combines the binding domain of the 
granulocyte colony-stimulating factor (GCSF) receptor with the transmembrane and a mutated 
cytoplasmic domain of the LIFR. This chimeric receptor lacks the binding site for the negative 
feedback regulator SOCS3 and can signal only via JAK/STAT3 activation and not through the 
MAPK/ERK- and PI3K-pathways. GCSF-induced STAT3 activation was shown to promote not only 
epiblast stem cell (EpiSC) to ESC conversion but also to increase the efficiency of generating  
Oct4-GFP+ cells from the partially reprogrammed iPSC line in cooperation with 2i.  
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Interestingly, phosphorylation of STAT3 did not result in the immediate induction of the 
pluripotency factors Nanog or Klf4 suggesting that the contribution of STAT3 in creating a poised state 
for reprogramming is obtained through the activation of additional target genes, which have not been 
identified yet.  
The role of LIF/STAT3 is still elusive also in the maintenance of iPSCs. In ESCs, the 
overexpression of STAT3 is sufficient to maintain ESCs pluripotent in the absence of LIF [18]. We 
generated iPSCs from fibroblasts overexpressing a tamoxifen inducible form of STAT3 (STAT3MER) 
and determined the iPSC-stability in culture by cultivating the cells under four different culture 
conditions (+LIF+OHT/+LIF-OHT/-LIF+OHT/-LIF-OHT). As expected, the cells cultivated in the 
presence of LIF were able to self-renew, whereas iPSCs maintained in the absence of LIF 
differentiated. Interestingly cells cultivated in medium supplemented with OHT but not LIF, were able 
to maintain their pluripotent state, as shown by SSEA-1 and OCT3/4 immunohistochemical analysis 
(Figure 2) and alkaline phosphatase activity. These findings clearly highlight the similarity between 
ESCs and iPSCs in respect to their LIF/STAT3 dependence. 
Figure 2. IHC staining of induced pluripotent stem cell (iPSC) clones expressing 
STAT3MER after 9 days in different culture conditions. iPSCs cultivated on Lif−/− feeders 
either in the presence of LIF, or LIF and OHT, or OHT alone were able to maintain their 
pluripotent state. Cells cultivated without LIF and OHT differentiated. Positive control: 
E14 ESCs cultivated in presence of LIF. Scale bar: 100 μm for 20× and 200 μm for  
10× pictures.  
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3. Experimental Section 
3.1. Generation and Cultivation of STAT3-MER iPSCs  
iPSCs cells were obtained by retroviral infection of STAT3MER mouse embryonic fibroblasts 
(MEFs) obtained from FVB/N STAT3MER (Tg743) [58] by using the pMXs-based retroviral 
reprogramming system [86,87]. Wild type and STAT3MER‐ expressing iPSC clones were seeded on 
LIF−/− feeders and cultivated in medium with or without LIF and in the presence or absence of  
4-hydroxy tamoxifen (Sigma). After 9 days in culture, cells were fixed and stained for pluripotency 
markers SSEA-1 and OCT3/4. 
3.2. Immunohistochemical Analysis of STAT3-MER iPSCs 
ESCs were fixed in 4% paraformaldehyde and incubated overnight at 4 °C with primary antibodies 
against OCT3/4 (rabbit anti OCT3/4, Santa Cruz Biotechnology) and SSEA-1 (Mouse mAb, Chemicon 
International). Secondary fluorescence labeled antibodies were used for detection (anti rabbit Alexa 
Fluor 594 and anti mouse Alexa Fluor 488, Molecular Probes). Nuclei of the cells were counterstained 
with DAPI (Roche). 
4. Conclusions 
In this review article, we summarized the actual knowledge on the importance of LIF in the 
maintenance of pluripotency and self-renewal in embryonic and induced pluripotent stem cells. The 
work performed over the past two decades by different research groups all over the world has 
identified the LIF-pathway as a crucial element for the regulation of self-renewal and for the 
maintenance of pluripotency in ESCs and iPSCs. Nevertheless, even though the LIF-mediated 
pathways in ESCs were extensively studied the precise mechanisms how they are regulated still remain 
unclear. Especially the role of STAT3 in reprogramming requires further analysis. The fact that Stat3 
activation during reprogramming does not result in the immediate induction of its known target genes 
is of interest, suggesting that the contribution of STAT3 in this process is obtained through the 
regulation of additional target genes. The identification of these genes and the further characterization 
of the mechanisms involved in maintenance of stem cells will be an important goal for the future. 
These studies are of major interest because ESCs and iPSCs have great potential for therapeutic 
applications, especially for tissue engineering, regenerative medicine and cell therapy. 
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